Sugi Predict

Sugi Predict / Compounds / SCHEMBL894559

SCHEMBL894559

SCHEMBL894559

CON(C)C(=O)[C@@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.54
▸ USP30 Q70CQ3 5/20 0.50
▸ RECQL P46063 1/20 0.48
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ EPHX1 P07099 1/20 0.45
▸ PTPN2 P17706 1/20 0.44
▸ PTPN1 P18031 1/20 0.44
▸ PTPN6 P29350 1/20 0.44
▸ JAK2 O60674 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ STS P08842 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ RIN1 Q13671 1/20 0.41
▸ USP2 O75604 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL389962 1.00 HPGD (0.54) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL586312 1.00 HPGD (0.54) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL442932 0.92 MEN1 (0.56) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL968401 0.92 MEN1 (0.56) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL1249710 0.92 MEN1 (0.56) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL407899 0.91 HPGD (0.56) HPGDRECQLKMT2AALDH1A1MAPT
SCHEMBL3615534 0.91 HPGD (0.53) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL278133 0.88 NR1H2 (0.45) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL2153593 0.87 HPGD (0.57) HPGDUSP30RECQLKMT2AALDH1A1
SCHEMBL14348065 0.87 HPGD (0.57) HPGDUSP30RECQLKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds ACERTA PHARMA B.V. (NL) 2026-05-05 — — US disclosed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 — — WO disclosed
US-12552786-B2 Inhibitors of αvβ6 integrin MORPHIC THERAPEUTIC, INC. (US) 2026-02-17 — — US disclosed
US-12528803-B2 Inhibitors of αvβ6 integrin MORPHIC THERAPEUTIC, INC. (US) 2026-01-20 — — US disclosed
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS ACERTA PHARMA BV (NL) 2025-11-27 — — US disclosed
EP-3843728-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2025-04-30 — — EP disclosed
EP-3844162-B1 INHIBITORS OF ALPHA V BETA6 INTEGRIN MORPHIC THERAPEUTIC INC (US) 2025-01-01 — — EP disclosed
US-20240335431-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS ACERTA PHARMA B.V. (NL) 2024-10-10 — — US disclosed
US-20230295113-A1 NLRP3 MODULATORS ZOMAGEN BIOSCIENCES LTD 2023-09-21 — — US disclosed
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2023-08-03 — — US disclosed
US-20110275694-A1 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS THERAVANCE, INC. (US) 2011-11-10 — — US disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 — — WO disclosed
WO-2011133653-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED (US) 2011-10-27 — — WO disclosed
US-7888386-B2 3-(phenoxyphenylmethyl)pyrrolidine compounds THERAVANCE, INC. (US) 2011-02-15 — — US disclosed
US-7888386-B2 3-(phenoxyphenylmethyl)pyrrolidine compounds THERAVANCE, INC. (US) 2011-02-15 — — US disclosed
US-7888386-B2 3-(phenoxyphenylmethyl)pyrrolidine compounds THERAVANCE, INC. (US) 2011-02-15 — — US disclosed
WO-2010011811-A2 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS THERAVANCE, INC. (US) 2010-01-28 — — WO disclosed
US-20100022616-A1 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2010-01-28 — — US disclosed
US-20100022616-A1 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2010-01-28 — — US disclosed
US-20100022616-A1 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS THERAVANCE BIOPHARMA R&D IP, LLC 2010-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242524-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV HPGD 3107/4885USP30 4257/4885RECQL 4410/4885
US-12552786-B2 Inhibitors of αvβ6 integrin ITGB6, ITGB1, ITGA6 HPGD 3206/4885USP30 4721/4885RECQL 4840/4885
US-20230295113-A1 NLRP3 MODULATORS NLRP3, NLRP1, NOD1 HPGD 964/4885USP30 1574/4885RECQL 1257/4885
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds MEN1, PKD1, PKD2 HPGD 2427/4885USP30 4846/4885RECQL 2122/4885
US-20110275694-A1 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS HTR6, SLC6A2, SLC6A4 HPGD 1213/4885USP30 4480/4885RECQL 516/4885
US-20240335431-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS MEN1, PKD1, ADCYAP1R1 HPGD 670/4885USP30 4736/4885RECQL 29/4885
US-20100022616-A1 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS HTR6, SLC6A2, SLC6A4 HPGD 1213/4885USP30 4480/4885RECQL 516/4885
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS MEN1, PKD1, ADCYAP1R1 HPGD 670/4885USP30 4736/4885RECQL 29/4885
US-12528803-B2 Inhibitors of αvβ6 integrin ITGB2, ITGB6, ITGA2 HPGD 3944/4885USP30 4848/4885RECQL 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.